Suzanne Ostrand-Rosenberg, PhD


  • English

Academic Information

  • Departments: Pathology - Adjunct Professor
  • Divisions: Microbiology and Immunology


Selected Publications

Journal Article

  1. Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg S (2018 Mar). Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. J Leukoc Biol, 103(3), 395-407.
  2. Adams KR, Chauhan S, Patel DB, Clements VK, Wang Y, Jay SM, Edwards NJ, Ostrand-Rosenberg S, Fenselau C (2018 Jan 5). Ubiquitin Conjugation Probed by Inflammation in Myeloid-Derived Suppressor Cell Extracellular Vesicles. J Proteome Res, 17(1), 315-324.
  3. Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S, El-Sayed NM, Fenselau C (2018 Jan 5). Differential Content of Proteins, mRNAs, and miRNAs Suggests that MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions. J Proteome Res, 17(1), 486-498.
  4. Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg S (2018 Jan). Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. Cancer Immunol Res, 6(1), 59-68.
  5. Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, Sinha P, Poudel M, Ostrand-Rosenberg S (2017 Aug 29). CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget, 8(35), 57964-57980.
  6. Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements VK (2017 May). Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. J Leukoc Biol, 101(5), 1091-1101.
  7. Chauhan S, Danielson S, Clements V, Edwards N, Ostrand-Rosenberg S, Fenselau C (2017 Jan 6). Surface Glycoproteins of Exosomes Shed by Myeloid-Derived Suppressor Cells Contribute to Function. J Proteome Res, 16(1), 238-246.
  8. Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, OLoughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS (2016 Dec 8). Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.LID - 10.7554/eLife.17375 [doi]LID - e17375 [pii]. eLife, 5.
  9. Geis-Asteggiante L, Ostrand-Rosenberg S, Fenselau C, Edwards NJ (2016 Nov 15). Evaluation of Spectral Counting for Relative Quantitation of Proteoforms in Top-Down Proteomics. Anal Chem, 88(22), 10900-10907.
  10. Parker KH, Horn LA, Ostrand-Rosenberg S (2016 Sep). High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. J Leukoc Biol, 100(3), 463-70.
  11. Choksawangkarn W, Graham LM, Burke M, Lee SB, Ostrand-Rosenberg S, Fenselau C, Edwards NJ (2016 Jul). Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways. Proteomics, 16(13), 1881-8.
  12. Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N, Ostrand-Rosenberg S (2016 Apr 15). Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2. J Immunol, 196(8), 3470-8.
  13. Ostrand-Rosenberg S (2016 Jan). Tolerance and immune suppression in the tumor microenvironment. Cell Immunol, 299, 23-9.
  14. Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E (2015 May 15). TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res, 75(10), 1959-1971.
  15. Geis-Asteggiante L, Dhabaria A, Edwards N, Ostrand-Rosenberg S, Fenselau C (2015 Feb 15). Top-down analysis of low mass proteins in exosomes shed by murine myeloid-derived suppressor cells. Int J Mass Spectrom, 378, 264-269.
  16. Burke MC, Oei MS, Edwards NJ, Ostrand-Rosenberg S, Fenselau C (2014 Dec 5). Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells. J Proteome Res, 13(12), 5965-72.
  17. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S (2014 Dec). Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol, 96(6), 1109-18.
  18. Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S (2014 Oct 15). HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res, 74(20), 5723-33.
  19. Haile ST, Horn LA, Ostrand-Rosenberg S (2014 Jul). A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Cancer Immunol Res, 2(7), 610-5.
  20. Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C (2014 Feb 7). Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J Proteome Res, 13(2), 836-43.
  21. Sinha P, Ostrand-Rosenberg S (2013 Nov). Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract. Cancer Immunol Immunother, 62(11), 1663-73.
  22. Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S (2013 Sep 1). Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol, 191(5), 2829-36.
  23. Ostrand-Rosenberg S (2013). Inflammation, immune suppression, and tumor progression. BMC Proc, 7 Suppl 2, K20.
  24. Chornoguz O, Gapeev A, ONeill MC, Ostrand-Rosenberg S (2012 Nov). Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Mol Cell Proteomics, 11(11), 1457-67.
  25. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ (2012 Aug). IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov, 2(8), 722-35.
  26. Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S (2012 Aug). Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha. Eur J Immunol, 42(8), 2052-9.
  27. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L (2011 Jul 1). Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J Biol Chem, 286(26), 23591-9.
  28. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S (2011 Jun 15). Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol, 186(12), 6822-9.
  29. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S (2011 May 19). Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood, 117(20), 5381-90.
  30. Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S (2011 Mar). Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics, 10(3), M110.002980.
  31. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA (2010 Dec). IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol, 40(12), 3347-57.
  32. Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ, Ostrand-Rosenberg S (2010 Dec 1). MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer, 127(11), 2612-21.
  33. van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM (2010 Dec). Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother, 59(12), 1825-38.
  34. van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA (2010 Mar). Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica, 95(3), 485-93.
  35. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S (2010 Jan 1). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res, 70(1), 68-77.
  36. Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S (2010 Jan). Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother, 59(1), 103-12.
  37. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM (2009 Sep). Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat, 117(2), 235-42.
  38. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S (2009 Jul 15). Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol, 183(2), 937-44.
  39. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S (2009 Jun). Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol, 85(6), 996-1004.
  40. Ostrand-Rosenberg S (2008 Dec). Cancer and complement. Nat Biotechnol, 26(12), 1348-9.
  41. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008 Oct 1). Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol, 181(7), 4666-75.
  42. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S (2008 Oct). Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother, 57(10), 1493-504.
  43. Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S (2008 Mar). The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother, 57(3), 389-98.
  44. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007 Oct 15). Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res, 67(20), 10019-26.
  45. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007 Jul 15). Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol, 179(2), 977-83.
  46. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007 May 1). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res, 67(9), 4507-13.
  47. Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S (2007 May 1). MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res, 67(9), 4499-506.
  48. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S (2006 Nov 1). Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol, 177(9), 6018-24.
  49. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S (2006 Feb 1). Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol, 176(3), 1447-55.
  50. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S (2006 Jan 15). Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res, 66(2), 1147-54.
  51. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006 Jan 1). Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol, 176(1), 284-90.
  52. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA (2005 Dec 19). A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med, 202(12), 1627-33.
  53. Sinha P, Clements VK, Ostrand-Rosenberg S (2005 Dec 15). Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res, 65(24), 11743-51.
  54. Dissanayake SK, Tuera N, Ostrand-Rosenberg S (2005 Feb 15). Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J Immunol, 174(4), 1811-9.
  55. Sinha P, Clements VK, Ostrand-Rosenberg S (2005 Jan 15). Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol, 174(2), 636-45.
  56. Ilkovitch D, Ostrand-Rosenberg S (2004 Jun). MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain. Cancer Immunol Immunother, 53(6), 525-32.
  57. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S (2004 Mar 15). Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res, 64(6), 2205-11.
  58. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S (2004 Mar 1). Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res, 64(5), 1867-74.
  59. Dolan BP, Phelan TP, Ilkovitch D, Qi L, Wade WF, Laufer TM, Ostrand-Rosenberg S (2004 Jan 15). Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines. J Immunol, 172(2), 907-14.
  60. Becart S, Setterblad N, Ostrand-Rosenberg S, Ono SJ, Charron D, Mooney N (2003 Jun 15). Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling. J Cell Sci, 116(Pt 12), 2565-75.
  61. Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK (2002 Nov 15). Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol, 169(10), 5796-804.
  62. Pulaski BA, Smyth MJ, Ostrand-Rosenberg S (2002 Aug 1). Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res, 62(15), 4406-12.
  63. Qi L, Ostrand-Rosenberg S (2001 Aug 1). H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens. J Immunol, 167(3), 1371-8.
  64. Ostrand-Rosenberg S (2001 May). Mouse SaI sarcoma tumor model. Curr Protoc Immunol, Chapter 20, Unit 20.3.
  65. Pulaski BA, Ostrand-Rosenberg S (2001 May). Mouse 4T1 breast tumor model. Curr Protoc Immunol, Chapter 20, Unit 20.2.
  66. Ostrand-Rosenberg S, Grusby MJ, Clements VK (2000 Dec 1). Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol, 165(11), 6015-9.
  67. Qi L, Rojas JM, Ostrand-Rosenberg S (2000 Nov 15). Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol, 165(10), 5451-61.
  68. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S (2000 May 15). Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res, 60(10), 2710-5.
  69. Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S (2000 Apr). Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother, 49(1), 34-45.
  70. Qi L, Ostrand-Rosenberg S (2000 Feb). MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic, 1(2), 152-60.
  71. Armstrong TD, Clements VK, Ostrand-Rosenberg S (1998 May). Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J Immunother, 21(3), 218-24.
  72. Pulaski BA, Ostrand-Rosenberg S (1998 Apr 1). Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res, 58(7), 1486-93.
  73. Armstrong TD, Clements VK, Ostrand-Rosenberg S (1998 Jan 15). MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol, 160(2), 661-6.
  74. Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK (1998). Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines. Adv Exp Med Biol, 451, 259-64.
  75. Laufer TM, Smiley ST, Ranger A, Clements VK, Ostrand-Rosenberg S, Glimcher LH (1997 Dec 15). Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation. J Immunol, 159(12), 5914-20.
  76. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S (1997 Jun 24). Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A, 94(13), 6886-91.
  77. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S (1996 May 15). Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol, 156(10), 3821-7.
  78. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK (1996 May). Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens, 47(5), 414-21.
  79. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S (1995 Feb 1). Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med, 181(2), 619-29.
  80. Baskar S, Azarenko V, Garcia Marshall E, Hughes E, Ostrand-Rosenberg S (1994 Apr 15). MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol, 155(1), 123-33.
  81. Lamouse-Smith E, Clements VK, Ostrand-Rosenberg S (1993 Dec 1). Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol, 151(11), 6283-90.
  82. Baskar S, Nabavi N, Glimcher LH, Ostrand-Rosenberg S (1993 Oct). Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother Emphasis Tumor Immunol, 14(3), 209-15.
  83. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993 Jun 15). Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A, 90(12), 5687-90.
  84. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S (1992 Oct 1). Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol, 149(7), 2391-6.
  85. Ostrand-Rosenberg S, Roby CA, Clements VK (1991 Oct 1). Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol, 147(7), 2419-22.
  86. Nishimura MI, Ostrand-Rosenberg S (1991 Sep). Mouse Hepa-1 tumor is rejected by H-2Db-restricted CTL despite decreased MHC class I antigen expression. Cell Immunol, 136(2), 414-24.
  87. Cole GA, Ostrand-Rosenberg S (1991 May). Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4-CD8+ T lymphocytes that are not lytic for the tumor. Cell Immunol, 134(2), 480-90.
  88. Ostrand-Rosenberg S, Roby C, Clements VK, Cole GA (1991). Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int J Cancer Suppl, 6, 61-8.
  89. Ostrand-Rosenberg S, Cole GA, Nishimura MI, Clements VK (1990 Jun). Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host. Cell Immunol, 128(1), 152-64.
  90. Ostrand-Rosenberg S, Thakur A, Clements V (1990 May 15). Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol, 144(10), 4068-71.
  91. Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA (1989 Aug-Oct). Transfection of major histocompatibility complex class I and class II genes causes tumour rejection. J Immunogenet, 16(4-5), 343-9.
  92. Ostrand-Rosenberg S, Nickerson DA, Clements VK, Garcia EP, Lamouse-Smith E, Hood L, Stroynowski I (1989 Jul). Embryonal carcinoma cells express Qa and Tla class I genes of the major histocompatibility complex. Proc Natl Acad Sci U S A, 86(13), 5084-8.
  93. Nishimura MI, Stroynowski I, Hood L, Ostrand-Rosenberg S (1988 Dec 15). H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma. J Immunol, 141(12), 4403-9.
  94. Davy CA, Tesfay Z, Jones J, McCarthy C, Ostrand-Rosenberg S, Rosenberg RC (1988 Feb). Endogenous superoxide dismutase and catalase activities and radiation resistance in mouse cell lines. Int J Radiat Biol Rlat Stud Phys Chem Med, 53(2), 283-9.
  95. Cole GA, Cole GA, Clements VK, Garcia EP, Ostrand-Rosenberg S (1987 Dec). Allogeneic H-2 antigen expression is insufficient for tumor rejection. Proc Natl Acad Sci U S A, 84(23), 8613-7.
  96. Ostrand-Rosenberg S, Clements V (1987). Resistance to 402AX teratocarcinoma involves immunity to minor histocompatibility antigens. Immunogenetics, 26(1-2), 1-5.
  97. Ostrand-Rosenberg S, Schwartzman ML, Hecht TT, Marr L (1986 May). Teratocarcinoma cell MHC antigen expression is regulated in vitro by a soluble noninterferon factor. Cell Immunol, 99(2), 453-60.
  98. Ostrand-Rosenberg S, Clements V, Marr L (1986 Apr 1). 402AX teratocarcinoma MHC class I antigen expression is regulated in vivo by Lyt 1, Lyt 2, and L3T4 expressing splenic T cells. Cell Immunol, 98(2), 257-65.
  99. Ostrand-Rosenberg S, Clements V, Cole G, DeCloux A, Marr L, Schwartzman M (1984 Dec). Regulation of major histocompatibility gene expression in teratocarcinoma 402AX cells. Cell Differ, 15(2-4), 221-7.
  100. Ostrand-Rosenberg S, McCarthy C (1984). Resistance to murine 402AX teratocarcinoma: regulation by H-2IA and H-3 to H-13 region genes. Immunogenetics, 19(1), 77-82.
  101. Ostrand-Rosenberg S, Cohn AL, Sandoz JW (1983 Jun). Multiple splenic lymphoid cell subpopulations regulate H-2 antigen expression on teratocarcinoma cells in vivo. J Immunol, 130(6), 2969-73.
  102. Ostrand-Rosenberg S, Cohn A (1981 Nov). H-2 antigen expression on teratocarcinoma cells passaged in genetically resistant mice is regulated by lymphoid cells. Proc Natl Acad Sci U S A, 78(11), 7106-10.
  103. Ostrand-Rosenberg S, Cohan VL (1981 Jun). H-2 negative teratocarcinoma cells become H-2 positive when passaged in genetically resistant host mice. J Immunol, 126(6), 2190-3.
  104. Teodorczyk-Injeyan J, Jewett MA, Burke CA, Ostrand-Rosenberg S (1980 Jun). Detection of the circulating antibodies to teratocarcinomadefined antigens in patients with testicular tumours. Clin Exp Immunol, 40(3), 438-44.
  105. Ostrand-Rosenberg S, Rider TM, Twarowski A (1980). Susceptibility of allogeneic mice to teratocarcinoma 402AX. Immunogenetics, 10(6), 607-12.
  106. Ostrand-Rosenberg S, Edidin M, Jewett MA (1977 Nov). Human teratoma cells share antigens with mouse teratoma cells. Dev Biol, 61(1), 11-9.
  107. Ostrand-rosenberg S (1976). Lack of identity of the A antigen and concanavalin A receptor on bovine erythrocytes; implications for membrane structure. Vox Sang, 30(4), 268-81.
  108. Ostrand-Rosenberg S (1975). Gene dosage and antigenic expression on the cell surface of bovine erythrocytes. Anim Blood Groups Biochem Genet, 6(2), 81-99.
  109. Ostrand-Rosenberg S, Stormont C (1974). Bovine leukocyte antigens. Anim Blood Groups Biochem Genet, 5(4), 231-7.


  1. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018 May). Understanding the tumor immune microenvironment (TIME) for effective therapy. [Review]. Nat Med, 24(5), 541-550.
  2. Ostrand-Rosenberg S (2018 Apr). Myeloid derived-suppressor cells: their role in cancer and obesity. [Review]. Curr Opin Immunol, 51, 68-75.
  3. Ostrand-Rosenberg S, Fenselau C (2018 Jan 15). Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. [Review]. J Immunol, 200(2), 422-431.
  4. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI (2016 Jul 6). Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. [Review]. Nat Commun, 7, 12150.
  5. Ostrand-Rosenberg S, Horn LA, Alvarez JA (2015 Oct). Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. [Review]. Cancer Immunol Immunother, 64(10), 1287-93.
  6. Parker KH, Beury DW, Ostrand-Rosenberg S (2015). Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. [Review]. Adv Cancer Res, 128, 95-139.
  7. Ostrand-Rosenberg S, Horn LA, Haile ST (2014 Oct 15). The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. [Review]. J Immunol, 193(8), 3835-41.
  8. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012 Aug). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. [Review]. Semin Cancer Biol, 22(4), 275-81.
  9. Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C (2012 Aug). Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). [Review]. Cancer Immunol Immunother, 61(8), 1319-25.
  10. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012 Mar 22). Coordinated regulation of myeloid cells by tumours. [Review]. Nat Rev Immunol, 12(4), 253-68.
  11. Ostrand-Rosenberg S (2010 Oct). Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. [Review]. Cancer Immunol Immunother, 59(10), 1593-600.
  12. Ostrand-Rosenberg S, Sinha P (2009 Apr 15). Myeloid-derived suppressor cells: linking inflammation and cancer. [Review]. J Immunol, 182(8), 4499-506.
  13. Ostrand-Rosenberg S (2008 Feb). Immune surveillance: a balance between protumor and antitumor immunity. [Review]. Curr Opin Genet Dev, 18(1), 11-8.
  14. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S (2005 Nov). Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. [Review]. Cancer Immunol Immunother, 54(11), 1137-42.
  15. Ostrand-Rosenberg S (2005). CD4+ T lymphocytes: a critical component of antitumor immunity. [Review]. Cancer Invest, 23(5), 413-9.
  16. Ostrand-Rosenberg S (2004 Apr). Animal models of tumor immunity, immunotherapy and cancer vaccines. [Review]. Curr Opin Immunol, 16(2), 143-50.
  17. Ostrand-Rosenberg S, Sinha P, Clements V, Dissanayake SI, Miller S, Davis C, Danna E (2004 Feb). Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. [Review]. Cancer Immunol Immunother, 53(2), 86-91.
  18. Ostrand-Rosenberg S, Sinha P, Danna EA, Miller S, Davis C, Dissanayake SK (2004). Antagonists of tumor-specific immunity: tumor-induced immune suppression and host genes that co-opt the anti-tumor immune response. [Review]. Breast Disease, 20, 127-35.
  19. Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA (1999 Aug). Cell-based vaccines for the stimulation of immunity to metastatic cancers. [Review]. Immunol Rev, 170, 101-14.
  20. Armstrong TD, Pulaski BA, Ostrand-Rosenberg S (1998 Apr). Tumor antigen presentation: changing the rules. [Review]. Cancer Immunol Immunother, 46(2), 70-4.
  21. Ostrand-Rosenberg S (1994 Oct). Tumor immunotherapy: the tumor cell as an antigen-presenting cell. [Review]. Curr Opin Immunol, 6(5), 722-7.
  22. Ostrand-Rosenberg S, Garcia EP, Roby CA, Clements VK (1991 Oct). Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection. [Review]. Semin Cancer Biol, 2(5), 311-9.
  23. Van Kaer L, Wu M, Ichikawa Y, Ito K, Bonneville M, Ostrand-Rosenberg S, Murphy DB, Tonegawa S (1991 Apr). Recognition of MHC TL gene products by gamma delta T cells. [Review]. Immunol Rev, 120, 89-115.
  24. Ostrand-Rosenberg S (1980). Cell-mediated immune responses to mouse embryonic cells: detection and characterization of embryonic antigens. [Review]. Curr Top Dev Biol, 14(Pt 2), 147-68.


  1. Ostrand-Rosenberg S (2013 Jan). Looking to the future of cancer immunotherapy: many questions to answer and many therapeutic opportunities. Cancer Immunol Immunother, 62(1), 1-2.


  1. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H (2007 Jan 1). The terminology issue for myeloid-derived suppressor cells [Letter to the editor]. Cancer Res, 67(1), 425; author reply 426.


  1. Pawelec G, Ostrand-Rosenberg S (2017 Jul). Professor Enrico Mihich, 1928-2016. Cancer Immunol Immunother (66(7), pp. 955-957). Germany.